Latest Research: CPT31, A Long-acting Peptide Drug, Has A Significant Effect On The Treatment Of AID

According to the World Health Organization (who), about 1.7 million people worldwide are newly infected with HIV in 2019. At present, more than 38 million people are infected with the disease. Combined antiretroviral therapy (Art), the so-called "drug cocktail", has greatly improved the survival rate and quality of life of such patients, but it is expensive, often has serious side effects, and requires patients to take medicine for a long time. In addition, drug resistance has always been a challenge due to the frequent variation of HIV, so researchers always seek new drugs and new mechanisms of action to produce more powerful combination therapy.

Recently, scientists have developed an injectable drug that can prevent HIV from entering cells. And the new drug has the potential to provide lasting protection against infection with fewer side effects. The drug, which has been tested in non-human primates, could eventually replace or complement the "cocktail" therapy currently used to prevent or treat viruses.

"This is an exciting new HIV treatment in prevention and treatment, with a unique mechanism of action compared to other approved drugs," said Dr. Michael S. Kay, senior author of the study and professor of Biochemistry at American University. "It has great potential to help patients with drug resistance and those who will benefit from a cocktail of long-lasting injections of anti HIV drugs.

In this new study, the researchers tested a unique drug called CPT31, which is based on D-peptide, which targets the key pocket of HIV fusion mechanism, which rarely mutates. D-peptide is the mirror image of naturally produced peptide. Think about our left and right hands. The building blocks and overall structure of natural peptides are similar to our left hand, while d-peptides are similar to our right hand.

Because CPT31 and other D-peptide will not degrade in vivo. Therefore, they last longer than natural peptides and are particularly suitable for long-term injectable preparations. In addition to its durability in vivo, D-peptide is largely ignored by the immune system, which prevents the immune response to the side effects often seen by traditional peptide and protein drugs.

The study was recently published in the proceedings of the National Academy of Sciences (PNAs).

For any requests of Vosoritide for research purpose, welcome to contact us. www.gtpeptide.com , sales1@gotopbio.com.